Merck's Keytruda Is Dealt a Legal Setback. It's Good News for This Biotech Stock.

A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。